LENVIMA: payments to doctors
Payments that named LENVIMA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $22.2M
- Providers
- 18,689
- Transactions
- 114,774
- Average per transaction
- $193
The per-transaction average — $193 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 18,689 providers the average total is $1,188, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Eisai Inc. | $15,164,680 | 68.3% |
| Merck | $6,742,618 | 30.4% |
| Eisai Co., Ltd. | $286,116 | 1.3% |
| Novartis | $392 | 0.0% |